Protalix BioTherapeutics Inc. (PLX)’s Financial Results Comparing With Karuna Therapeutics Inc. (NASDAQ:KRTX)

Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) and Karuna Therapeutics Inc. (NASDAQ:KRTX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protalix BioTherapeutics Inc. N/A -0.08 145.04M -0.18 0.00
Karuna Therapeutics Inc. 37 0.00 11.93M -1.27 0.00

In table 1 we can see Protalix BioTherapeutics Inc. and Karuna Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 has Protalix BioTherapeutics Inc. and Karuna Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics Inc. 60,008,274,720.73% 0% 0%
Karuna Therapeutics Inc. 31,847,303.79% 0% 0%

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for Protalix BioTherapeutics Inc. and Karuna Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Protalix BioTherapeutics Inc. 0 0 0 0.00
Karuna Therapeutics Inc. 0 0 1 3.00

On the other hand, Karuna Therapeutics Inc.’s potential upside is 56.52% and its consensus target price is $109.

Insider & Institutional Ownership

Protalix BioTherapeutics Inc. and Karuna Therapeutics Inc. has shares owned by institutional investors as follows: 9.7% and 0.3%. 6.23% are Protalix BioTherapeutics Inc.’s share owned by insiders. On the other hand, insiders owned about 33.1% of Karuna Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Protalix BioTherapeutics Inc. -3.35% -20.23% -11.35% -11.37% -22.74% 20.55%
Karuna Therapeutics Inc. -9.21% -12.71% 0% 0% 0% -8.44%

For the past year Protalix BioTherapeutics Inc. has 20.55% stronger performance while Karuna Therapeutics Inc. has -8.44% weaker performance.


On 5 of the 9 factors Protalix BioTherapeutics Inc. beats Karuna Therapeutics Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.